Parathyroid hormone levels: the lower the better the outcomes

Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease, particularly in patients receiving dialysis. Conventional management has emphasized avoiding excessively low PTH levels to prevent low-turnover bone disease, yet recent evidence challenges this approach. This review examines the potential of more intensive PTH control to improve skeletal and clinical outcomes.

Although excessive suppression of PTH or low-turnover bone has been thought to impair bone strength, recent evidence indicates that intensive PTH reduction does not compromise bone integrity and may even reduce fracture risk. PTH-lowering interventions appear to limit further progression of SHPT-associated cortical porosity but cannot reverse established structural damage, underscoring the importance of early intervention. Low-turnover bone has also been hypothesized to impair calcium buffering and promote vascular calcification; however, its clinical impact seems limited in the era of widespread calcimimetic use or following parathyroidectomy. Furthermore, there is no clear evidence that excessive PTH suppression adversely affects nonskeletal organs influenced by SHPT.

These findings suggest that the benefits of more intensive PTH control may outweigh potential risks, supporting a proactive management approach. Prospective interventional studies are needed to confirm whether this strategy can reduce fractures and improve survival without safety concerns.